mCRC
![Companion Diagnostic for Encorafenib + Cetuximab in BRAF V600E alteration in mCRC Receives FDA Approval](https://pharmtales.com/wp-content/uploads/2023/06/Companion-Diagnostic-for-Encorafenib-Plus-Cetuximab-in-BRAF-V600E-mCRC-Receives-FDA-Approval.jpg)
Companion Diagnostic for Encorafenib + Cetuximab in BRAF V600E alteration in mCRC Receives FDA Approval
SG Tylor
Source – Foundation Medicine In order to identify patients with metastatic colorectal cancer (mCRC) who could be candidates to receive ...